Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Orders Label Revisions for 44 APIs in Sleep/Anxiolytic/Epilepsy Agents
March 21, 2017
- MHLW Unveils Revised Label Format; Notification Due Out Early FY2017
March 21, 2017
- MHLW Ordinance Will Close Loopholes in Clinical Research Bill’s Funding Disclosure Rules: Bureau Chief
March 21, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Japan Healthcare Spending Logs Slight Rise on Subdued Hep C Sales in April-September
March 17, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Recovering Trust in Clinical Research Is Urgent Task: Shiozaki
March 17, 2017
- MHLW Panel Initiates Discussions on Whether to Lift Ban on Export of Blood Products
March 17, 2017
- AMED Begins Taking Applications for Funding for Drug Discovery Environments
March 17, 2017
- Optimal Use Guidelines for Additional Indications to Be Reported to Chuikyo after Issuance
March 16, 2017
- Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
- Chuikyo Subcommittee OKs 5-Scale Rating for Cost Effective Assessments
March 16, 2017
- Spontaneous Reporting Required Even When Causal Relationship Is Unclear: MHLW
March 16, 2017
- Chuikyo Approves Optimal Use Promotion Guidelines for Repatha, Praluent
March 16, 2017
- Ex-Minister Tamura, 17 Healthcare Leaders to Launch Study Group
March 15, 2017
- MHLW to Up Ante on Drug Distribution, Launch Panel on March 29: Minister
March 15, 2017
- PMDA’s FY2017 Project Plan Sets Higher Goal for Standard Product Review
March 15, 2017
- PMDA Approves Draft Budget for FY2017
March 15, 2017
- PMDA’s Steering Committee Discusses Fines, Regulatory Revision in Wake of Kaketsuken Scandal
March 15, 2017
- Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…